OncoMed Pharmaceuticals To Present Phase 1a Data In Advanced Solid Tumor Patients For The First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) At The European Cancer Congress 2013 (ECC 2013)

Updated clinical data to be presented for vantictumab at ECC 2013

Vantictumab, a program partnered with Bayer Pharma AG, is advancing to three combination Phase 1b studies in selected tumor types

REDWOOD CITY, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported that new data for vantictumab, a monoclonal antibody targeting the WNT pathway, will be presented at a poster session at the Joint ECCO 17, 38th ESMO and 32nd ESTRO European Cancer Congress 2013 (ECC 2013) in Amsterdam, The Netherlands.

The poster presentation called "A phase I study in patients with advanced solid tumors for the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway" will be presented in the Poster Session "Drug Development" on Sunday, September 29, 2013 from 09:30 to 12:00 CET. The presenting author is Dr. David Smith from the University of Michigan Cancer Center at Ann Arbor, MI, on behalf of the other principal investigators Dr. Lee Rosen at the University of California, Los Angeles, CA, Dr. Kyriakos Papadopoulos at The START Center for Cancer Care, San Antonio, TX and the entire study team.

Vantictumab is a first-in-class monoclonal antibody that has broad anti-cancer stem cell and anti-tumor activity in patient-derived xenograft tumor models. In the ongoing Phase 1a trial, vantictumab is well tolerated in advanced solid tumor patients. Vantictumab shows pharmacodynamic effects on the WNT pathway in patient samples. OncoMed is planning to initiate Phase 1b trials in three tumor indications to study its safety in combination with standard-of-care chemotherapy. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer Pharma AG.

Paul Hastings, Chairman and Chief Executive Officer of OncoMed noted, "We have made excellent progress with vantictumab and our other clinical program targeting the WNT pathway, Fzd8-Fc (also known as OMP-54F28). We look forward to presenting the updated data for vantictumab in advanced solid tumor patients at the European Cancer Congress 2013 in Amsterdam."

If you liked this article you might like

Biotech Movers: Horizon, OncoMed, Inovio

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data